A new study led by investigators at National Jewish Health and published in Annals of Allergy, Asthma & Immunology shows that treatment with dupilumab significantly restores skin barrier function and ...

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisApproval in adults and ...

Dupilumab yields rapid reductions in nasal polyp burden and improvements in smell function; these benefits persist with extended dosing intervals.

Overall, the CUPID-C trial corroborates earlier evidence that dupilumab can meaningfully reduce itch and hives in ...

The FDA has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis.

CEO Nello Mainolfi had one line on the February 26, 2026 earnings call that deserves attention beyond the headline numbers: his company just put the first IRF5-directed therapy in human history into ...

Phase 3 LIBERTY-AIMS results showed dupilumab reduced nasal polyp size and sinus symptoms in adults and children with allergic fungal rhinosinusitis.

Please provide your email address to receive an email when new articles are posted on . 47.6% of patients tolerated changes in dosing from every 2 weeks to every 4 weeks. Patients who did not tolerate ...

Phase II data suggest fewer GI adverse effects when given a sequence of biologics ...

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled ...

BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy.